Log in

Relevant bibliographies by topics / Antineoplastic Anthracyclines Anthracyclines Crystallography

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Antineoplastic Anthracyclines Anthracyclines Crystallography'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antineoplastic Anthracyclines Anthracyclines Crystallography.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antineoplastic Anthracyclines Anthracyclines Crystallography"

1

Zucchi, Riccardo, and Romano Danesi. "Cardiac Toxicity of Antineoplastic Anthracyclines." Current Medicinal Chemistry-Anti-Cancer Agents 3, no. 2 (March 1, 2003): 151–71. http://dx.doi.org/10.2174/1568011033353434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Luo, Dasan, and Steven R. Vincent. "Inhibition of nitric oxide synthase by antineoplastic anthracyclines." Biochemical Pharmacology 47, no. 11 (June 1994): 2111–12. http://dx.doi.org/10.1016/0006-2952(94)90088-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Brunetti, Luigi, Giustino Orlando, Barbara Michelotto, Lucia Recinella, Enzo Ragazzoni, and Michele Vacca. "A possible prolactin-related adverse effect of certain antineoplastic anthracyclines." Toxicology Letters 116, no. 3 (August 2000): 231–36. http://dx.doi.org/10.1016/s0378-4274(00)00223-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Creutzig, Ursula, Sylke Diekamp, Martin Zimmermann, and Dirk Reinhardt. "Long Term Data on Anthracycline Cardiotoxicity in 547 Children with AML." Blood 108, no. 11 (November 1, 2006): 2014. http://dx.doi.org/10.1182/blood.v108.11.2014.2014.

Full text

Abstract:

Abstract Anthracyclines are effective antineoplastic drugs in acute mylogenous leukemia (AML) and dose intensity and cumulative doses are especially important. However, the use of anthracyclines is limited by cardiotoxicity, which occurs already at 300 mg/m2 cumulative doses (given as daunorubicin dosage) in children. To evaluate anthracycline-associated cardiomyopathy in pediatric AML-patients, the incidence of late clinical and subclinical cardiotoxicity (using echocardiography) was analysed in studies AML-BFM 93 and 98. Out of a total of 1,207 patients under 18 years, 547 (45%) patients were eligible for the analysis of late cardiotoxicity - de novo AML: 470 of 1,010 (46%), AML-Down syndrome: 69 of 121 (57%), secondary AML 8 of 76 (11%) -, median follow-up 5.3 years (0.8–11.7 years) after diagnosis. The cumulative dose of anthracyclines was risk-adapted between 300 and 450 mg/m2 or even higher in patients with secondary AML. Results: Late cardiomyopathy was seen in 16 patients, cumulative incidence (CI) after 11 years 5±1% (de novo patients: 4±1%), including 4 of 38 patients (10.5%) who suffered already from early cardiomyopathy. Nine of these 16 patients (CI 2.5±1%) showed clinical symptoms, with persistent abnormal shortening fraction in 5 of them, which led to death in one AML-Down syndrome patient. Late subclinical cardiomyopathy occurred temporarily in 7 patients. Late clinical cardiomyopathy mainly effected patients with a second anthracycline therapy (3 of 8 with AML as secondary malignancy) and those with early cardiotoxicity. Using anthracyclines risk-adapted or administering long-term infusion might have contributed to the low rate of cardiomyopathy in AML de novo patients.

APA, Harvard, Vancouver, ISO, and other styles

5

Dolinsky, Vernon W. "The role of sirtuins in mitochondrial function and doxorubicin-induced cardiac dysfunction." Biological Chemistry 398, no. 9 (August 28, 2017): 955–74. http://dx.doi.org/10.1515/hsz-2016-0316.

Full text

Abstract:

Abstract Anthracycline chemotherapeutics such as doxorubicin continue to be important treatments for many cancers. Through improved screening and therapy, more patients are surviving and living longer after the diagnosis of their cancer. However, anthracyclines are associated with both short- and long-term cardiotoxic effects. Doxorubicin-induced mitochondrial dysfunction is a central mechanism in the cardiotoxic effects of doxorubicin that contributes to impaired cardiac energy levels, increased reactive oxygen species production, cardiomyocyte apoptosis and the decline in cardiac function. Sirtuins are protein deacetylases that are activated by low energy levels and stimulate energy production through their activation of transcription factors and enzymatic regulators of cardiac energy metabolism. In addition, sirtuins activate oxidative stress resistance pathways. SIRT1 and SIRT3 are expressed at high levels in the cardiomyocyte. This review examines the function of sirtuins in the regulation of cardiac mitochondrial function, with a focus on their role in heart failure and an emphasis on their effects on doxorubicin-induced cardiotoxicity. We discuss the potential for sirtuin activation in combination with anthracycline chemotherapy in order to mitigate its cardiotoxic side-effects without reducing the antineoplastic activity of anthracyclines.

APA, Harvard, Vancouver, ISO, and other styles

6

Vermorken, J. B. "The role of anthracyclines in second-line therapy of ovarian cancer." International Journal of Gynecologic Cancer 13, Suppl 2 (2003): 178–84. http://dx.doi.org/10.1136/ijgc-00009577-200311001-00009.

Full text

Abstract:

Anthracyclines (ANTs) have been in clinical practice since the 1960s and represent one of the most commonly used classes of anticancer drugs. In the 1990s, meta-analyses showed a favorable impact of doxorubicin (DOX/A) on the survival of patients with advanced ovarian cancer, when it was combined with cyclophosphamide and cisplatin (CAP) and compared to CP alone. With the acceptance of paclitaxel-carboplatin (TCb) as the new reference arm for first-line treatment, testing the addition of ANTs to TCb seems a logic next step. Trials presently testing this, make use of either epirubicin (EPI) or pegylated liposomal doxorubicin (PLD: Doxil®/Caelyx®). These are the two most favorable ANTs, based on data obtained with various ANTs in ovarian cancer failing platinum-based chemotherapy. EPI has not been evaluated in direct comparison with other antineoplastic agents. PLD has been compared with both paclitaxel and topotecan. No difference in efficacy parameters could be observed, but the toxicity profile of PLD scored favorably against those of the comparator in both trials, despite the fact that palmar-plantar erythrodysesthesia can be troublesome, and sometimes lead to treatment discontinuation. Data from four randomized trials evaluating the role of ANT combinations in patients with relapsed ovarian cancer suggest that the addition of EPI or DOX to paclitaxel does not lead to better outcomes in patients with platinum-refractory or resistant disease. In platinum-sensitive disease, any benefit of EPI-platinum or DOX-platinum combinations over platinum alone is uncertain. There are no randomized trials with PLD combinations in the second-line setting. It is concluded that both EPI and PLD can be recommended as a reasonable single-agent treatment option for relapsed patients, with a preference for PLD taking into account its more favorable toxicity profile.

APA, Harvard, Vancouver, ISO, and other styles

7

Sartor, Lauren, Charmaine Ibarra, Ahmad Al-Mestarihi, Brian O. Bachmann, and Jessica L. Vey. "Structure of DnmZ, a nitrososynthase in the Streptomyces peucetius anthracycline biosynthetic pathway." Acta Crystallographica Section F Structural Biology Communications 71, no. 10 (September 23, 2015): 1205–14. http://dx.doi.org/10.1107/s2053230x15014272.

Full text

Abstract:

The anthracyclines are a class of highly effective natural product chemotherapeutics and are used to treat a range of cancers, including leukemia. The toxicity of the anthracyclines has stimulated efforts to further diversify the scaffold of the natural product, which has led to renewed interest in the biosynthetic pathway responsible for the formation and modification of this family of molecules. DnmZ is an N-hydroxylating flavin monooxygenase (a nitrososynthase) that catalyzes the oxidation of the exocyclic amine of the sugar nucleotide dTDP-L-epi-vancosamine to its nitroso form. Its specific role in the anthracycline biosynthetic pathway involves the synthesis of the seven-carbon acetal moiety attached to C4 of L-daunosamine observed in the anthracycline baumycin. Here, X-ray crystallography was used to elucidate the three-dimensional structure of DnmZ. Two crystal structures of DnmZ were yielded: that of the enzyme alone, solved to 3.00 Å resolution, and that of the enzyme in complex with thymidine diphosphate, the nucleotide carrier portion of the substrate, solved to 2.74 Å resolution. These models add insights into the structural features involved in substrate specificity and conformational changes involved in thymidine diphosphate binding by the nitrososynthases.

APA, Harvard, Vancouver, ISO, and other styles

8

Hashizume, Makoto. "Experimental Studies on the Effect of Antineoplastic Drugs, Especially of Anthracyclines, and Coenzyme Q10 on Human Platelets." Journal of Kansai Medical University 37, no. 4 (1985): 534–59. http://dx.doi.org/10.5361/jkmu1956.37.4_534.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Aceves, Carmen, Yunuen Alfaro-Hernandez, and Guadalupe Delgado. "Abstract B38: Iodine supplement exerts antineoplastic adjuvancy, chemoresistance inhibition and cardioprotection in mammary cancer treatment with anthracyclines." Cancer Prevention Research 5, no. 11 Supplement (November 2012): B38. http://dx.doi.org/10.1158/1940-6207.prev-12-b38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kulyova, Svetlana A., Tatiana Yu Semiglazova, Daria A. Zvyagintseva, Margarita B. Belogurova, Svetlana V. Ivanova, and Irina V. Okisheva. "Cardiovascular complications of antineoplastic therapy in children." Pediatrician (St. Petersburg) 8, no. 3 (May 15, 2017): 130–41. http://dx.doi.org/10.17816/ped83130-141.

Full text

Abstract:

The improvement of long-term survival in children with malignant tumors is noted in the last five decades. Serious late consequences of the applied therapy including early death, the second tumors, different organ dysfunctions (heart, gonads, liver, lungs) began to come to light with increase in number of cured and follow-up. The article discusses the emergence of cardiotoxicity in children treated with cytostatic and radiation therapy for malignant tumors. Particular attention is paid to the influence of anthracycline antibiotics on the state of the heart muscle. Anthracycline and similar medicines - doxorubicin, rubomycin, idarubicin, mitoxantrone - are an important component of most regimen of chemotherapy in children. Briefly describes the history of the application of this group of drugs in oncology and the study of their effects on heart function. The attention to the pathogenesis of anthracycline cardiotoxicity risk factors for its development, display options, how to identify and mitigate. We describe the clinical manifestations of early and late cardiotoxicity arising after the application of antitumor antibiotics anthracyclines. The article defines the role of chemotherapeutic agents other groups in the development and worsening cardiotoxicity. No less important role in the development of long-term effects of the heart and blood vessels plays radiotherapy. The paper paid attention to cardiovascular dysfunctions that arise in different periods of observation after irradiation of the mediastinum. Finally, recommendations for practitioners on screening, monitoring and treatment of identified diseases of the cardiovascular system in patients cured of childhood malignancies are presented.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Antineoplastic Anthracyclines Anthracyclines Crystallography"

1

Sultana, Azmiri. "Mechanistic insights into the biosynthesis of polyketide antibiotics /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7357-010-9/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ellenberger, William Paul. "Synthesis of DEF ring synthons to nogarol anthracyclines /." Full text open access at:, 1987. http://content.ohsu.edu/u?/etd,136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mancini, Michael. "Approaches to the synthesis of xanthone analogs of the anthracycline class of anticancer agents." Thesis, McGill University, 1985. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=72059.

Full text

Abstract:

Several strategies outlining approaches to the synthesis of the heteroanthracyclinones 4-demethoxyxanthodaunomycinone and 4-demethoxyisoxanthodaunomycinone (7,8,9,10-tetrahydrobenzo(b)-6,7,9,11-tetrahydroxy-9-acetylxanthen-12 and 5-one) are described.
The condensation of tetralin 2-acetyl-5,8-dimethoxy-1,2,3,4-tetrahydro-2-naphthol with o-methoxybenzoic acid was investigated and useful large-scale syntheses of important 1,4-dimethoxy-substituted xanthone intermediates were developed.
Diels-Alder cycloaddition reaction between a xanthone-derived o-quinodimethane intermediate and an olefin afforded a low yield of adduct. On the other hand, excellent yields of isolable but labile adducts were obtained in the cycloaddition reaction between xanthoquinone (and also thioxanthoquinone) and Danishefsky's dienes. The formation of linear vs internal adducts was rationalized on the grounds of resonance and FMO theory. Efforts to induce unactivated dienes to cycloadd using catalysts as well as annulation studies on model compounds using the novel reagent (E)-N-vinylpyrrolidine-(beta)-(2-lithio-1,3-dithian-2-yl) (as a synthon of the (alpha),(beta)-dianion of acetaldehyde) are discussed.
The synthesis of daunomycin and xanthodaunomycin analogs carrying a carbon substituent at position 7 were not accessible using the Diels-Alder cycloaddition reaction as diene 1-carbomethoxy-3-triethylsilyloxy-1,3-butadiene failed to react with either quinizarinquinone or xanthoquinone even at elevated temperatures.
The compound 4-hydroxy-1- 2- (2-hydroxyethyl)amino ethyl amino xanthone and the 4-methoxy derivative were prepared and found to be inactive in the in vivo P-388 mouse leukemia model system.

APA, Harvard, Vancouver, ISO, and other styles

4

Baghdanov, Vaceli M. "Synthetic studies of naturally occurring hydroxylated polycyclic compounds : daunomycinone and pillaromycinone /." Full text open access at:, 1987. http://content.ohsu.edu/u?/etd,142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Jansson, Anna. "Structural enzymology of the biosynthesis of polyketide antibiotics /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-916-1/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Fiallo, Maria Lorenzo. "Une Nouvelle classe d'antitumoraux : les complexes metal-anthracyclines, synthèse, caractéristiques physicochimiques et propriétés tumorales." Paris 13, 1986. http://www.theses.fr/1986PA132003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

BENZINEB, KOUIDER, and Christiane Bonnelle. "Activation par radiolyse pulsee et par radiolyse gamma d'un medicament antitumoral : la daunorubicine, en presence de peptides et de proteines." Paris 6, 1988. http://www.theses.fr/1988PA066071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kuschak, Theodore I. "Selection of an ICRF-187-resistant CHO cell line and measurement of cytotoxicity, additive cytotoxicity, and cross-resistance of bisdioxopiperazines, anthracyclines, and other antineoplastic agents in wildtype and resistant cells." 1994. http://hdl.handle.net/1993/18148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antineoplastic Anthracyclines Anthracyclines Crystallography"

1

1948-, Priebe Waldemar, and American Chemical Society. Division of Carbohydrate Chemistry., eds. Anthracycline antibiotics: New analogues, methods of delivery, and mechanisms of action. Washington, DC: American Chemical Society, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

William, Lown J., ed. Anthracycline and anthracenedione-based anticancer agents. Amsterdam: Elsevier, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Karsten, Krohn, ed. Anthracycline chemistry and biology. Berlin: Springer, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

M, Muggia Franco, Green Michael D. 1949-, and Speyer James L, eds. Cancer treatment and the heart. Baltimore: Johns Hopkins University Press, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Timothy, Bricker J., Green Daniel M, and D'Angio Giulio J. 1922-, eds. Cardiac toxicity after treatment for childhood cancer. New York: Wiley-Liss, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antineoplastic Anthracyclines Anthracyclines Crystallography"

1

"CARDIOTOXICITY OF ANTHRACYCLINES AND OTHER ANTINEOPLASTIC AGENTS." In Cardiovascular Toxicology, 384–410. CRC Press, 2001. http://dx.doi.org/10.3109/9780203361450-20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antineoplastic Anthracyclines Anthracyclines Crystallography"

1

Alfaro, Y., G. Delgado, and C. Aceves. "Abstract P5-10-16: Iodine/Anthracyclines Is the Best Combination Against Mammary Cancer. Antineoplastic Synergism and Cardioprotection." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p5-10-16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Peralta, Guillermo, Jose Miguel Torres, Guadalupe Delgado, Adriana Dominguez, Rodrigo De Obaldía, Luis Duarte, Eduardo Paredes, et al. "Abstract 3509: Iodine exhibits dual effects on breast cancer as a co-treatment with anthracyclines: Antineoplastic synergy and cardioprotector." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!